#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	8132	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2088	382.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1410	1410	C	424	C	419	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14594	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	412.3	0	.	n	.	0	A20C	SNP	20	20	A	326	326	C	259	C,A	252,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14594	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	412.3	0	.	n	.	0	T695C	SNP	695	695	T	1001	1001	C	463	C	460	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14594	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	412.3	0	.	n	.	0	A1638G	SNP	1638	1638	A	1944	1944	G	478	G	467	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14594	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	412.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2277	2277	C	435	C,T,G	421,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14594	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	412.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2351	2351	A	444	A	434	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14594	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	412.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2903	2903	C	458	C	451	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1148	folP	855	855	100.0	folP.l15.c4.ctg.1	1553	73.1	1	SNP	p	R229S	1	.	.	685	687	AGC	997	999	AGC	105;103;102	A;G;C	104;102;99	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	2960	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3369	86.9	1	SNP	p	S91F	1	.	.	271	273	TTC	586	588	TTC	96;95;98	T;T;C,T	94;93;96,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	2960	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3369	86.9	1	SNP	p	D95G	1	.	.	283	285	GGC	598	600	GGC	103;101;101	G;G;C	100;97;97	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	2960	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3369	86.9	1	SNP	p	G95N	0	.	.	283	285	GGC	598	600	GGC	103;101;101	G;G;C	100;97;97	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1034	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1301	78.4	1	SNP	p	G45D	0	.	.	133	135	GGC	450	452	GGC	128;126;130	G;G,T;C,T	128;125,1;129,1	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	464	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c17.ctg.1	976	47.1	0	.	n	.	0	G98A	SNP	98	98	G	496	496	A	109	A	105	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	464	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c17.ctg.1	976	47.1	0	.	n	.	0	A197.	DEL	197	197	A	594	594	A	102	A	102	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	2804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3057	90.9	1	SNP	p	D86N	0	.	.	256	258	GAC	564	566	GAC	110;111;111	G;A;C	107;108;109	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	2804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3057	90.9	1	SNP	p	R87I	0	.	.	259	261	CGT	567	569	CGT	111;113;115	C;G;T	110;108;110	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	2804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3057	90.9	1	SNP	p	R87W	0	.	.	259	261	CGT	567	569	CGT	111;113;115	C;G;T	110;108;110	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	2804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3057	90.9	1	SNP	p	S87R	1	.	.	259	261	CGT	567	569	CGT	111;113;115	C;G;T	110;108;110	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	2804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3057	90.9	1	SNP	p	S88P	0	.	.	262	264	TCC	570	572	TCC	115;114;117	T;C;C	112;108;115	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2246	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2603	85.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1512	1514	GGC	109;109;108	G;G;C	108;107;104	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	2166	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2524	84.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1294	1296	GCA	119;120;120	G,T;C;A	116,1;117;119	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2166	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2524	84.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1297	1299	ATC	120;121;121	A;T;C	118;118;118	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2166	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2524	84.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1309	1311	GTG	119;120;119	G;T;G	116;113;118	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2166	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2524	84.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1309	1311	GTG	119;120;119	G;T;G	116;113;118	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2166	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2524	84.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1813	1815	ACC	100;99;99	A,C;C;C	94,1;96;94	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2166	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2524	84.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1867	1869	GCG	89;89;90	G;C,G;G	85;73,3;85	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2166	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2524	84.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1867	1869	GCG	89;89;90	G;C,G;G	85;73,3;85	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2166	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2524	84.9	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1990	1992	AGC	100;100;100	A;G;C	97;97;98	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2166	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2524	84.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1999	2001	GGC	91;88;87	G;G;C	89;87;86	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2166	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2524	84.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2017	2019	CCG	69;71;73	C;C;G,T	65;67;69,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	3042	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3188	94.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1669	1671	CCG	114;113;114	C,G;C;G	102,1;109;109	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1250	porA	1146	1146	99.91	porA.l15.c30.ctg.1	1885	65.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	545	545	C	82	C	72	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	184	porB1a	984	112	91.96	porB1a.l15.c30.ctg.2	386	21.9	0	.	p	.	0	M18T	NONSYN	52	54	ATG	264	266	ACG	48;47;45	A;C;G	47;46;45	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	184	porB1a	984	112	91.96	porB1a.l15.c30.ctg.2	386	21.9	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	306	308	CAA	20;19;16	C;A;A	20;19;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	184	porB1a	984	112	91.96	porB1a.l15.c30.ctg.2	386	21.9	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	312	314	TAC	11;10;10	T;A;C	11;10;10	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1480	porB1b	1047	1047	98.66	porB1b.l15.c17.ctg.1	1617	90.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	544	546	GAA	123;123;123	G;A;A	122;121;122	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1480	porB1b	1047	1047	98.66	porB1b.l15.c17.ctg.1	1617	90.7	0	.	p	.	0	K41D	NONSYN	121	123	AAA	553	555	GAC	121;121;122	G;A;C	120;119;121	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1480	porB1b	1047	1047	98.66	porB1b.l15.c17.ctg.1	1617	90.7	0	.	p	.	0	K120N	NONSYN	358	360	AAG	790	792	AAT	115;115;116	A;A;T	111;115;116	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1480	porB1b	1047	1047	98.66	porB1b.l15.c17.ctg.1	1617	90.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	955	957	TCA	117;121;123	T;C;A	115;117;119	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1480	porB1b	1047	1047	98.66	porB1b.l15.c17.ctg.1	1617	90.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1084	1086	GTC	128;127;127	G;T;C	124;122;124	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1480	porB1b	1047	1047	98.66	porB1b.l15.c17.ctg.1	1617	90.7	0	.	p	.	0	A242V	NONSYN	724	726	GCC	1156	1158	GTT	135;136;137	G;T;T	133;134;134	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1480	porB1b	1047	1047	98.66	porB1b.l15.c17.ctg.1	1617	90.7	0	.	p	.	0	D333V	NONSYN	997	999	GAC	1429	1431	GTC	109;108;108	G;T;C	108;105;107	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1480	porB1b	1047	1047	98.66	porB1b.l15.c17.ctg.1	1617	90.7	1	SNP	p	D121N	0	.	.	361	363	GAC	793	795	GAC	116;116;116	G;A;C	116;114;115	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1480	porB1b	1047	1047	98.66	porB1b.l15.c17.ctg.1	1617	90.7	1	SNP	p	A121D	1	.	.	361	363	GAC	793	795	GAC	116;116;116	G;A;C	116;114;115	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	5328	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4983	106.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	710	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1123	62.6	1	SNP	p	V57M	1	.	.	169	171	ATG	632	634	ATG	137;138;139	A;T;G	137;137;138	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
